IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM
https://doi.org/10.15690/pf.v9i3.318
Abstract
The respiratory syncytial viral (RSV) infection is the leading cause of lower respiratory infections (bronchiolitis, pneumonia) in young children. Premature children and children with an inherent heart defect experience a heavy course of the infection, they require treatment in the resuscitation department, oxygen therapy and ALV. This article summarizes the first experience in Russia of executing a regional program on immunoprophylaxis of the RSV infection using monoclonal RDV-antibodies prepared with palivizumab among the following categories of children: premature children, children with a bronchopulmonary dysplasia and an inherent heart defect. The inclusion of palivizumab into the rehabilitation program of these categories of patients allowed to decrease the frequency of lower respiratory infections and corresponding hospitalizations by 4.6 and 4.8 times respectively. Not a single patient out of the 5 hospitalized with a lower respiratory infection, immunized with palivizumab, had his treatment connected with RSV. A high level of the drug’s safety was also determined — none of the children experienced any sort of unwanted effects.
About the Authors
A. A. Korsunskiy
Moscow Healthcare Department
Russian Federation
Russian Federation
D. Y. Ovsannikov
Peoples’ Friendship University, Moscow
6th Children’s Infectious Hospital, Moscow
Russian Federation
Russian Federation
D. N. Degtarev
Moscow Healthcare Department
Kulakov Scientific Center of Obstetrics, Gynecology and Perinatology, Moscow
Russian Federation
Russian Federation
I. N. Yakovleva
Moscow Healthcare Department
Russian Federation
Russian Federation
E. A. Degtareva
Peoples’ Friendship University, Moscow
6th Children’s Infectious Hospital, Moscow
Russian Federation
Russian Federation
E. L. Bokeriya
Moscow State Hospital № 67
Russian Federation
Russian Federation
E. S. Keshishan
Moscow State Hospital № 13
Scientific Research Institute of Pediatrics and Child Surgery, Moscow
Russian Federation
Russian Federation
O. V. Shamsheva
Moscow Healthcare Department
Russian Federation
Russian Federation
E. S. Pavlova
6th Children’s Infectious Hospital, Moscow
Russian Federation
Russian Federation
I. V. Krsheminskaya
Peoples’ Friendship University, Moscow
Russian Federation
Russian Federation
Z. S. Igityan
6th Children’s Infectious Hospital, Moscow
Russian Federation
Russian Federation
H. M. Markhulia
Scientific Research Institute of Pediatrics and Child Surgery, Moscow
Russian Federation
Russian Federation
E. D. Balashova
Scientific Research Institute of Pediatrics and Child Surgery, Moscow
Russian Federation
Russian Federation
G. A. Alamovskaya
Scientific Research Institute of Pediatrics and Child Surgery, Moscow
Russian Federation
Russian Federation
O. V. Mironyuk
Moscow State Hospital № 8
Russian Federation
Russian Federation
O. V. Potapova
Moscow State Hospital № 8
Russian Federation
Russian Federation
References
1. Shay D. K., Holman R. C., Newman R. D. et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999; 282: 1440–1446.
2. Fleming D. M., Elliot A. J., Cross K. W. Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiol. Infect. 2007; 12: 1–10.
3. Thompson W. W., Shay D. K., Weintraub E. et al. Mortalality associated with influenza and respiratory syncytial virus in the united states. JAMA. 2003; 289: 179–186.
4. Tatochenko V. K. et al. Epidemiology of respiratory syncytial virus in children < 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clinical Epidemiology. 2010; 2: 221–227.
5. Овсянников Д. Ю. Острый бронхиолит у детей. Вопросы практической педиатрии. 2010; 5 (2): 75–84.
6. Gorelick M. H., Singh B. S. Неотложные состояния при патологии дыхательной системы. Секреты неотложной педиатрии / пер. с англ. под ред. Н. П. Шабалова. М.: МЕД-пресс-информ. 2006. С. 277–291.
7. Wijaya H., Szabo S., Gooch K. et al. Elevated risk of asthma after hospitalization for severe respiratory syncytial virus infection in infancy: A systematic review and evidence synthesis. Paediatric Infectious Diseases Meeting — ESPID. 2011. P. 631.
8. Boyce T. G., Mellen B. G., Mitchel E. F. et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. 2000; 137 (6): 865–870.
9. Greenough A. Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO. Ped. Resp. Rev. 2009; 1 (10): 26–28.
10. Simon A. et al. Respiratory syncytial virus infection in 406 hospitalised premature infants: results from a prospective German multicentre database. Eur. J. Pediatr. 2007; 166: 1273–1283.
11. Checchia P. A., Nalysnyk L., Fernandes A. W. et al. Mortality and and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophilaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011; 12 (5): 580–588.
12. Immunoprophilaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr. Infect. Dis. J. 1999; 18: 223–231.
13. Navas L., Wang E., de Carvalho V. et al. Improved outcome of respiratory syncytial virus infection in a high-risk population of Canadian children. J. Pediatr. 1992; 121: 348–353.
14. Moler F. W. et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit. Care. Med. 1992; 20: 1406–1413.
15. Баранов А. А., Намазова-Баранова Л. С., Куличенко Т. В. и др. Факторы, определяющие длительность госпитализации детей с тяжелой респираторной синцитиальной вирусной инфекцией в России. Педиатрическая фармакология. 2011; 8 (6): 61–66.
16. Овсянников Д. Ю., Кршеминская И. В., Дегтярев Д. Н. Течение и терапия респираторно-синцитиального вирусного бронхиолита у недоношенных детей и детей с бронхолегочной дисплазией. Вопросы диагностики в педиатрии. 2012; 4 (3).
17. Glezen W. P. et al. Risk of respirtory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J. Pediatr. 1981; 98: 708–715.
18. Moylett E. H., O’Donovan D. J. Бронхиолит, грипп, вирусная пневмония. В кн.: Клейн Дж., Заутис Т. Е. Секреты лечения детских инфекций / пер. с англ. М.: Бином. 2007. C. 111–122.
19. Bloemers B. L. P. et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis — a prospective birth-cohort study. Pediatrics. 2007; 120: 1076–1081.
20. Wilkesmann A., Ammann R. A., Schildgen O. et al. Hospitalized children with respirtory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated cource. Pediatr. Infect. Dis. J. 2007; 26: 485–491.
21. Овсянников Д. Ю., Дегтярева Е. А., Кузьменко Л. Г. Группы риска тяжелого течения респираторно-синцитиальной вирусной инфекции у детей: современные возможности профилактики. Детские инфекции. 2011; 10 (2): 49–51.
22. American academy of pediatrics subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006; 118: 1774–1793.
23. Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children. NHS quality improvement scotland [Internet] available from. URL: www.sign.ac.uk [cited January 16, 2009].
24. Kapikian A. Z., Mitchell R. H., Chanock R. M. et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 1969; 89: 405–421.
25. American academy of pediatrics, policy statement modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124 (6): 1–73.
26. Nakazawa M. Guidelines for the use of the palivizumab in infant and yang children with congenital heart disesease. International Paediatrics. 2006; 48: 190–193.
27. Инструкция по применению Синагис (утверждена главным санитарным врачом РФ Г. Г. Онищенко 19.11.2009).
28. Вишнева Е. А., Намазова-Баранова Л. С., Торшхоева Р. М. и др. Паливизумаб: новые возможности профилактики астмы? Педиатрическая фармакология. 2011; 8 (3): 70–74.
29. Turti T. V., Baibarina E. N., Degtiareva E. A. et al. Safety and efficacy of Palivizumab prophylaxis in infants at high risk of severe respiratory syncytial virus (RSV) infection in the Russian Federation. Europediatrics. 2011. С. 138–219.
30. Намазова-Баранова Л. С., Давыдова И. В., Турти Т. В. и др. Современные возможности иммунопрофилактики тяжелого течения респираторно-синцитиальной вирусной инфекции у детей с последствиями перинатальной патологии. Педиатрическая фармакология. 2011; 8 (4): 92–100.
31. Куличенко Т. В., Намазова-Баранова Л. С., Торшхоева Р. М. и др. Анти-IgE-терапия бронхиальной астмы у детей: двухлетний опыт. Педиатрическая фармакология. 2010; 7 (3): 76–84.
32. Овсянников Д. Ю. Система оказания медицинской помощи детям, страдающим бронхолегочной дисплазией. Руководство для практикующих врачей / под ред. Л. Г. Кузьменко. М.: МДВ. 2010. 152 с.
33. Дегтярёва Е. А., Павлова Е. С., Овсянников Д. Ю., Вавилова Г. Н. Пневмония у младенцев с врожденными пороками сердца. Педиатрия. 2011; 90 (6): 164.
34. Рудакова А. В. Эффективность затрат на профилактику тяжелой респираторно-синцитиальной вирусной инфекции у недоношенных детей. Клиническая фармакология и фармакоэкономика. 2010; 3 (1): 13–18.
Review
For citations:
Korsunskiy A.A., Ovsannikov D.Y., Degtarev D.N., Yakovleva I.N., Degtareva E.A., Bokeriya E.L., Keshishan E.S., Shamsheva O.V., Pavlova E.S., Krsheminskaya I.V., Igityan Z.S., Markhulia H.M., Balashova E.D., Alamovskaya G.A., Mironyuk O.V., Potapova O.V. IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM. Pediatric pharmacology. 2012;9(3):22-31. (In Russ.) https://doi.org/10.15690/pf.v9i3.318
Views:
760
Email this article 